TuHURA Biosciences (HURA) Registration filing summary

Company overview and business model

• Clinical-stage immuno-oncology company focused on overcoming resistance to cancer immunotherapies through three core technology platforms: IFx innate immune agonists, TBS-2025 VISTA-inhibiting antibodies, and Delta Opioid Receptor (DOR) modulators targeting myeloid-derived suppressor cells.

• Lead product IFx-2.0 is in a Phase 3 trial for advanced/metastatic Merkel cell carcinoma as adjunctive therapy to pembrolizumab, using the FDA's accelerated approval pathway.

• TBS-2025, acquired via Kineta merger, is a VISTA-inhibiting monoclonal antibody targeting immunosuppression in AML, with a planned Phase 2 trial in combination with menin inhibitors.

• DOR technology is being developed for bi-specific antibody-peptide and antibody-drug conjugates to modulate the tumor microenvironment and prevent T cell exhaustion.

• Business model includes internal R&D, strategic acquisitions, and plans for development/commercial partnerships.

Financial performance and metrics

• Net loss of $22.6 million for the year ended December 31, 2024, and $6.7 million for the three months ended March 31, 2025; accumulated deficit of $117.8 million as of March 31, 2025.

• Cash and cash equivalents of $6.2 million as of March 31, 2025; cash runway projected through late Q4 2025.

• No product revenue to date; operations funded primarily through private placements, convertible notes, and equity offerings.

• Research and development expenses were $13.3 million in 2024 and $4.6 million for Q1 2025, reflecting increased clinical activity.

Use of proceeds and capital allocation

• Proceeds from recent private placements and warrant exercises are allocated to fund the Kineta acquisition, Phase 3 IFx-2.0 trial, advancement of TBS-2025 to Phase 2, and general working capital.

• June 2025 private placement raised $12.6 million, with tranches tied to clinical and merger milestones; additional $3.7 million to be funded by year-end 2025.